Matinas BioPharma Holdings Income Statement 2025-2011 | MTNB

Brief overview of revenue and earnings at Matinas BioPharma Holdings

This overview is based on financial performance over the past five years. According to figures from Matinas BioPharma Holdings, revenue changed from $120 thousand to $1.1 million over five years. The cumulative result was +815.2%, corresponding to roughly 55.7% per year. Sales grew at a rate typical of a strong expansion phase.

EBITDA was −14.4 million dollars at the beginning and −23.4 million dollars at the end of the period (−62.1%). The operating result developed less favorably than sales. EBITDA margin moved from −12048.6% to −2133.3%. Higher profitability strengthens the quality of operating growth.

Across the five years, the net result shifted from −14.1 million dollars to −22.9 million dollars. The negative result deepened, showing weaker final efficiency.

The market value of the business moved from $96.1 million to $1.6 million, or −98.3%. Lower capitalization reflects weaker investor expectations.

Summary assessment

The financial trajectory is weak and requires a cautious interpretation. The strongest signals are revenue expansion and higher operating efficiency. Caution is warranted because of lower net income, limited operating profitability and a weaker market valuation. Investors should continue to monitor margins, costs, and earnings quality.